Could a common diabetes drug help transplanted kidneys survive longer?

NCT ID NCT07555106

Ongoing Disease control Sponsor: University of Guadalajara Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dapagliflozin, a drug usually used for diabetes, can improve kidney function in people who have received a kidney from a living donor. Fifty-four adult transplant recipients will take either dapagliflozin or standard care for 12 months. Researchers will measure changes in kidney function, scarring, and overall health to see if the drug offers extra protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin (a diabetes drug that may also protect the kidneys)
What this could lead to: If it works, this could point toward a way to help transplanted kidneys last longer and work better.
What could go wrong: This is a small, early-phase trial with only 54 people, so results may not apply to everyone. The drug could also increase the risk of infections or other side effects in transplant patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT KIDNEY TRANSPLANT FAILURE

Contacts and locations

Locations

Universidad de Guadalajara

Guadalajara, Jalisco, 44250, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.